Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
France
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Normosang (human hemin, as heme arginate) replenishes heme and suppresses the overproduction of porphyrin precursors that drive acute porphyria attacks. It is indicated for the treatment of:
Normosang is approved in Europe; it is a different formulation from the US-approved hemin product (Panhematin) and is not itself FDA-approved. It is a prescription medicine and must be administered under the supervision of a qualified specialist experienced in treating acute porphyria.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Normosang (human hemin) injection may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Normosang (human hemin injection) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Normosang is not commercially marketed in India.
However, patients in India can legally access Normosang through the Named Patient Program (NPP) — an import provision that allows patients to receive medicines approved in other countries but not yet marketed in India, under a doctor's prescription and proper regulatory documentation.
Normosang is approved in Europe for the treatment of acute attacks of hepatic porphyria, ensuring full transparency throughout the process.
Normosang can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.
Normosang is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant, cold-chain logistics to preserve product integrity from dispatch to delivery.
Named Patient Program supports access to Normosang for patients with acute hepatic porphyria across major cities in India, coordinating documentation, sourcing, and delivery with treating specialists.
Patients in Mumbai can access Normosang through NPP with support from treating specialists at the city's leading centers.
In Delhi, NPP coordinates with hospitals and specialty metabolic clinics to facilitate timely access to Normosang.
Bangalore's genetics and metabolic disorder centers work with NPP to support patients requiring Normosang.
Patients in Chennai can access Normosang through NPP, with coordination between treating doctors and the program's regulatory and logistics team.
Hyderabad's metabolic and genetic testing centers support diagnosis and access coordination for Normosang through NPP.
NPP facilitates access to Normosang for patients in Kolkata under the guidance of treating specialists.
Patients in Pune can access Normosang through NPP with prescription-based coordination and cold-chain delivery support.
NPP supports access to Normosang for patients in Ahmedabad, working directly with treating specialists.
Patients in Kochi and across Kerala can access Normosang through NPP's regulated import pathway.
NPP coordinates access to Normosang for patients in Chandigarh and the surrounding region.
Patients in Jaipur can access Normosang through NPP with support from treating specialists.
NPP facilitates access to Normosang for patients in Lucknow and across Uttar Pradesh.
Patients in Bhubaneswar can access Normosang through NPP's coordinated import and delivery process.
NPP supports access to Normosang for patients in Guwahati and across the Northeast region.
NPP also supports access for patients in other Indian cities not listed above — contact the team to check availability and timelines for your location.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message